[Treatment of amyotrophic lateral sclerosis with ribonucleotides].

Abstract

In the treatment of 31 patients with lateral amyotrophical sclerosis the authors used the preparation ENKAD containing a complex of mono- and oligoribonucleotides. In 6 cases there was aggravation of the condition while in 18 of the observed cases--improvement. In 7 patients the condition was not altered. The treatment was convened under biochemical control (the assessment of the uric acid in the blood serum and urine and the excretion of oxypurine in the urine). It was possible to depict definite clinicobiochemical correlations. The conclusion is made that ENKAD can be used in the early stages of the disease and mainly in focal segmentary-nuclear lesions. The preparation is contraindicated in generalization of the process and in impetuous development of the disorder.

• Authors: T L Bunina, O A Khondkarian, T S Korshunova, E G Larskiĭ, B B Fuks
• Journal: Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952) (Zh Nevropatol Psikhiatr Im S S Korsakova) Vol. 76 Issue 2 Pg. 166-74 ( 1976) ISSN: 0044-4588 [Print] Russia (Federation)
• Vernacular Title: Lechenie bokovogo amiotroficheskogo skleroza ribonukleotidami
• PMID: 1266475 (Publication Type: English Abstract, Journal Article)

Chemical References

• Nucleotides
• Ribonucleotides

Topics

• Adult
• Amyotrophic Lateral Sclerosis (blood, drug therapy, urine)
• Female
• Humans
• Male
• Middle Aged
• Nucleotides (blood, urine)
• Ribonucleotides (administration & dosage, therapeutic use)
• Time Factors